ELAVL3

Summary

ELAVL3 (ELAV like RNA binding protein 3, HGNC:3314) is a protein-coding gene on chromosome 19p13.2, encoding ELAV-like protein 3 (Q14576). RNA-binding protein that binds to AU-rich element (ARE) sequences of target mRNAs, including VEGF mRNA.

A member of the ELAVL protein family, ELAV-like 3 is a neural-specific RNA-binding protein which contains three RNP-type RNA recognition motifs. The observation that ELAVL3 is one of several Hu antigens (neuronal-specific RNA-binding proteins) recognized by the anti-Hu serum antibody present in sera from patients with paraneoplastic encephalomyelitis and sensory neuronopathy (PEM/PSN) suggests it has a role in neurogenesis. Two alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.

Source: NCBI Gene 1995 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 32 total
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_001420

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3314
Approved symbol	ELAVL3
Name	ELAV like RNA binding protein 3
Location	19p13.2
Locus type	gene with protein product
Status	Approved
Aliases	HUC, PLE21, DKFZp547J036, HUCL, MGC20653
Ensembl gene	ENSG00000196361
Ensembl biotype	protein_coding
OMIM	603458
Entrez	1995

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 6 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000359227, ENST00000438662, ENST00000588853, ENST00000592218, ENST00000897487, ENST00000897488, ENST00000897489

RefSeq mRNA: 2 — MANE Select: NM_001420 NM_001420, NM_032281

CCDS: CCDS32912, CCDS45978

Canonical transcript exons

ENST00000359227 — 7 exons

Exon	Start	End
ENSE00000679896	11458061	11458286
ENSE00001435063	11480600	11481046
ENSE00001642939	11457110	11457148
ENSE00001662307	11466172	11466275
ENSE00001798757	11458458	11458611
ENSE00002769023	11451326	11454877
ENSE00003597348	11466608	11466827

Expression profiles

Bgee: expression breadth ubiquitous, 258 present calls, max score 99.06.

FANTOM5 (CAGE): breadth broad, TPM avg 3.0238 / max 488.4674, expressed in 236 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
179245	2.2865	226
179243	0.5264	101
179244	0.1892	79
208691	0.0216	9

Top tissues by expression

282 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
inferior vagus X ganglion	UBERON:0005363	99.06	gold quality
postcentral gyrus	UBERON:0002581	99.03	gold quality
parietal lobe	UBERON:0001872	98.97	gold quality
cortical plate	UBERON:0005343	98.80	gold quality
entorhinal cortex	UBERON:0002728	98.72	gold quality
ventral tegmental area	UBERON:0002691	98.45	gold quality
superior vestibular nucleus	UBERON:0007227	98.37	gold quality
ganglionic eminence	UBERON:0004023	98.10	gold quality
cerebellar cortex	UBERON:0002129	97.94	gold quality
paraflocculus	UBERON:0005351	97.93	gold quality
cerebellar hemisphere	UBERON:0002245	97.91	gold quality
cerebellar vermis	UBERON:0004720	97.91	gold quality
pons	UBERON:0000988	97.88	gold quality
type B pancreatic cell	CL:0000169	97.87	gold quality
cerebellum	UBERON:0002037	97.82	gold quality
right hemisphere of cerebellum	UBERON:0014890	97.79	gold quality
superior frontal gyrus	UBERON:0002661	97.78	gold quality
subthalamic nucleus	UBERON:0001906	97.37	gold quality
buccal mucosa cell	CL:0002336	97.35	gold quality
medulla oblongata	UBERON:0001896	97.33	gold quality
olfactory bulb	UBERON:0002264	97.30	gold quality
middle frontal gyrus	UBERON:0002702	97.24	gold quality
occipital lobe	UBERON:0002021	97.20	gold quality
dorsal plus ventral thalamus	UBERON:0001897	96.95	gold quality
primary visual cortex	UBERON:0002436	96.64	gold quality
frontal pole	UBERON:0002795	96.36	gold quality
Brodmann (1909) area 23	UBERON:0013554	96.06	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	95.96	gold quality
temporal lobe	UBERON:0001871	95.80	gold quality
spinal cord	UBERON:0002240	95.74	gold quality

Single-cell (SCXA)

Detected in 7 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-MTAB-6108	yes	225.90
E-MTAB-7316	yes	15.34
E-GEOD-137537	yes	6.37
E-HCAD-10	yes	4.74
E-HCAD-5	no	17.34
E-ANND-3	no	1.78
E-MTAB-6142	no	0.94

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

174 targeting ELAVL3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-9983-3P	99.94	71.48	3631

Literature-anchored findings (GeneRIF, showing 3)

• HuC expression in neuroblastoma (PMID:12209604)
• MiR-124 synergism with ELAVL3 enhances target gene expression to promote neuronal maturity. (PMID:34031238)
• Nuclear depletion of RNA-binding protein ELAVL3 (HuC) in sporadic and familial amyotrophic lateral sclerosis. (PMID:34618203)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	elavl3	ENSDARG00000014420
mus_musculus	Elavl3	ENSMUSG00000003410
rattus_norvegicus	Elavl3	ENSRNOG00000013752

Paralogs (24): ELAVL1 (ENSG00000066044), PABPC1 (ENSG00000070756), RBMS2 (ENSG00000076067), PABPC4 (ENSG00000090621), PABPC1L (ENSG00000101104), ELAVL2 (ENSG00000107105), RBM24 (ENSG00000112183), TARDBP (ENSG00000120948), HNRNPR (ENSG00000125944), RBM38 (ENSG00000132819), SYNCRIP (ENSG00000135316), SF3B4 (ENSG00000143368), RBMS3 (ENSG00000144642), PABPC3 (ENSG00000151846), RBMS1 (ENSG00000153250), RBM45 (ENSG00000155636), ELAVL4 (ENSG00000162374), PABPC5 (ENSG00000174740), PUF60 (ENSG00000179950), PABPC1L2B (ENSG00000184388), PABPC1L2A (ENSG00000186288), RBM34 (ENSG00000188739), RBM14 (ENSG00000239306), PABPC4L (ENSG00000254535)

Protein

Protein identifiers

ELAV-like protein 3 — Q14576 (reviewed: Q14576)

Alternative names: Hu-antigen C, Paraneoplastic cerebellar degeneration-associated antigen, Paraneoplastic limbic encephalitis antigen 21

All UniProt accessions (2): Q14576, K7EPB5

UniProt curated annotations — full annotation on UniProt →

Function. RNA-binding protein that binds to AU-rich element (ARE) sequences of target mRNAs, including VEGF mRNA. May also bind poly-A tracts via RRM 3. May be involved in neuronal differentiation and maintenance. Plays a role in the stabilization of GAP43 mRNA and in spatial learning.

Subunit / interactions. Interacts with MAP1B light chain LC1.

Tissue specificity. Brain specific.

Domain organisation. RRM 1 and RRM 2 bind cooperatively to AU-rich sequences in target mRNAs. RRM 3 binds to poly-A mRNA sequences.

Similarity. Belongs to the RRM elav family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q14576-1	1	yes
Q14576-2	2

RefSeq proteins (2): NP_001411, NP_115657 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000504	RRM_dom	Domain
IPR002343	Hud_Sxl_RNA	Family
IPR003954	RRM_euk-type	Domain
IPR006548	ELAD_HU_SF	Family
IPR012677	Nucleotide-bd_a/b_plait_sf	Homologous_superfamily
IPR034915	HuC_RRM3	Domain
IPR035979	RBD_domain_sf	Homologous_superfamily

Pfam: PF00076

UniProt features (15 total): sequence conflict 10, domain 3, chain 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14576-F1	76.57	0.53

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 190 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_DN, GSE45365_NK_CELL_VS_CD11B_DC_UP, BENPORATH_ES_WITH_H3K27ME3, MYOGENIN_Q6, PEREZ_TP63_TARGETS, GCANCTGNY_MYOD_Q6, ATACCTC_MIR202, TGACCTY_ERR1_Q2, GGGTGGRR_PAX4_03, CAGCTG_AP4_Q5, HANN_RESISTANCE_TO_BCL2_INHIBITOR_UP, MARTORIATI_MDM4_TARGETS_NEUROEPITHELIUM_DN, AML_Q6, MYCMAX_01, USF_01

GO Biological Process (2): nervous system development (GO:0007399), cell differentiation (GO:0030154)

GO Molecular Function (5): mRNA 3’-UTR AU-rich region binding (GO:0035925), nucleic acid binding (GO:0003676), RNA binding (GO:0003723), mRNA 3’-UTR binding (GO:0003730), protein binding (GO:0005515)

GO Cellular Component (1): ribonucleoprotein complex (GO:1990904)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
system development	1
cellular developmental process	1
mRNA 3’-UTR binding	1
nucleic acid binding	1
mRNA binding	1
protein-containing complex	1

Protein interactions and networks

STRING

2236 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ELAVL3	FABP7	O15540	630
ELAVL3	NEUROG2	Q9H2A3	614
ELAVL3	LGALS4	P56470	603
ELAVL3	GFAP	P14136	601
ELAVL3	NEUROG1	Q92886	600
ELAVL3	SOX10	P56693	586
ELAVL3	FAM98A	Q8NCA5	569
ELAVL3	ISL1	P20663	559
ELAVL3	ZFP36	P26651	552
ELAVL3	HES5	Q5TA89	551
ELAVL3	DHX36	Q9H2U1	545
ELAVL3	PAX6	P26367	527
ELAVL3	S100B	P04271	524
ELAVL3	EWSR1	Q01844	524
ELAVL3	OLIG2	Q13516	521

IntAct

34 interactions, top by confidence:

A	B	Type	Score
SYNGAP1	ELAVL3	psi-mi:“MI:0915”(physical association)	0.680
ELAVL3	SYNGAP1	psi-mi:“MI:0915”(physical association)	0.680
SYNGAP1	IGF2BP3	psi-mi:“MI:0914”(association)	0.530
ELAVL2	IGF2BP3	psi-mi:“MI:0914”(association)	0.530
DYRK1A	ELAVL3	psi-mi:“MI:0915”(physical association)	0.500
SCN2A	ELAVL3	psi-mi:“MI:0915”(physical association)	0.500
DYRK1A	IGF2BP3	psi-mi:“MI:0914”(association)	0.500
ELAVL3	A2M	psi-mi:“MI:0915”(physical association)	0.370
CDC37	ELAVL3	psi-mi:“MI:0915”(physical association)	0.370
ELAVL3	ECSIT	psi-mi:“MI:0915”(physical association)	0.370
MAST1	ELAVL3	psi-mi:“MI:0915”(physical association)	0.370
ELAVL3	NOS3	psi-mi:“MI:0915”(physical association)	0.370
ELAVL3	RNF32	psi-mi:“MI:0915”(physical association)	0.370
ELAVL3	EWSR1	psi-mi:“MI:0915”(physical association)	0.370
LIN28A	MEX3A	psi-mi:“MI:0914”(association)	0.350
CEP63	CIBAR1	psi-mi:“MI:0914”(association)	0.350
CEP135	WDR91	psi-mi:“MI:0914”(association)	0.350
SCN2A	IGLL5	psi-mi:“MI:0914”(association)	0.350
DYRK1A	TEX13D	psi-mi:“MI:0914”(association)	0.350
RIMS1	KIF2A	psi-mi:“MI:0914”(association)	0.350
HCN1	USP27X	psi-mi:“MI:0914”(association)	0.350
SYNGAP1	POTEF	psi-mi:“MI:0914”(association)	0.350
CACNA1C	SNRPGP15	psi-mi:“MI:0914”(association)	0.350
SYNGAP1	POM121C	psi-mi:“MI:0914”(association)	0.350
SYNGAP1	IGLON5	psi-mi:“MI:0914”(association)	0.350
PABPC5	APOBEC3DE	psi-mi:“MI:0914”(association)	0.350
GPM6A	KIF2A	psi-mi:“MI:0914”(association)	0.350
DAZL	HSPD1	psi-mi:“MI:0914”(association)	0.350

BioGRID (68): EWSR1 (Two-hybrid), ELAVL3 (Affinity Capture-MS), PEX14 (Co-fractionation), ELAVL3 (Biochemical Activity), ELAVL3 (Affinity Capture-MS), ELAVL3 (Affinity Capture-MS), ELAVL3 (Affinity Capture-MS), ELAVL3 (Affinity Capture-MS), ELAVL3 (Affinity Capture-MS), ELAVL3 (Affinity Capture-MS), ELAVL3 (Two-hybrid), ELAVL3 (Affinity Capture-MS), ELAVL3 (Affinity Capture-MS), ELAVL3 (Affinity Capture-MS), ELAVL3 (Proximity Label-MS)

ESM2 similar proteins: A0A0R4IEW8, A4QNI8, B5DF91, O01671, O09032, O17310, O61374, O64380, O95758, O97018, P16914, P19339, P26378, P26599, P42731, P70372, P86049, Q12926, Q14576, Q15717, Q1JQ73, Q24668, Q28FX0, Q28GD4, Q29099, Q5R9H4, Q5R9Z6, Q5U259, Q5YD48, Q60899, Q60900, Q61701, Q6DEY7, Q6GLB5, Q6GR16, Q6YZW2, Q7SZT7, Q8CH84, Q8GZ26, Q8LFS6

Diamond homologs: A0A0R4IEW8, A4QNI8, A8NS61, A8WLV5, B3M3R5, B3NGA1, B4HUE4, B4IX08, B4KX02, B4LFQ9, B4MM23, B4PIS2, B4QRJ0, B5DF91, B8BCZ8, O01671, O04425, O09032, O17310, O61374, O75821, O89086, O97018, P16914, P19339, P19683, P23241, P26378, P28644, P29558, P49310, P60824, P60825, P60826, P70372, P98179, Q04836, Q12926, Q14011, Q14498

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
ELAVL3	“down-regulates quantity”	ANK3	“post transcriptional regulation”
ELAVL3	“up-regulates quantity”	ADAM10	“post transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

32 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	25
Likely benign	2
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1506 predictions. Top by Δscore:

Variant	Effect	Δscore
19:11457105:GTTAC:G	donor_loss	1.0000
19:11457106:TTAC:T	donor_loss	1.0000
19:11457107:TAC:T	donor_loss	1.0000
19:11457109:C:CT	donor_loss	1.0000
19:11457109:CCT:C	donor_gain	1.0000
19:11457144:CCAGC:C	acceptor_gain	1.0000
19:11457145:CAGC:C	acceptor_gain	1.0000
19:11457145:CAGCC:C	acceptor_gain	1.0000
19:11457147:GCCT:G	acceptor_loss	1.0000
19:11457148:CCTG:C	acceptor_loss	1.0000
19:11457149:C:CC	acceptor_gain	1.0000
19:11458055:GCTCA:G	donor_loss	1.0000
19:11458056:CTCA:C	donor_loss	1.0000
19:11458057:TCA:T	donor_loss	1.0000
19:11458058:CA:C	donor_loss	1.0000
19:11458059:A:AC	donor_gain	1.0000
19:11458059:ACCGG:A	donor_loss	1.0000
19:11458060:C:CC	donor_gain	1.0000
19:11458284:CAC:C	acceptor_gain	1.0000
19:11458285:ACCTG:A	acceptor_loss	1.0000
19:11458287:C:CC	acceptor_gain	1.0000
19:11458288:T:C	acceptor_loss	1.0000
19:11458291:C:CT	acceptor_gain	1.0000
19:11458291:C:T	acceptor_gain	1.0000
19:11458292:A:T	acceptor_gain	1.0000
19:11458451:G:GA	donor_gain	1.0000
19:11458453:CTGA:C	donor_loss	1.0000
19:11458454:TGA:T	donor_loss	1.0000
19:11458455:GAC:G	donor_loss	1.0000
19:11458456:ACC:A	donor_loss	1.0000

AlphaMissense

2403 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:11454550:C:A	K360N	1.000
19:11454550:C:G	K360N	1.000
19:11454552:T:C	K360E	1.000
19:11454553:G:C	F359L	1.000
19:11454553:G:T	F359L	1.000
19:11454554:A:G	F359S	1.000
19:11454555:A:G	F359L	1.000
19:11454558:A:G	S358P	1.000
19:11454560:A:T	V357D	1.000
19:11454566:A:C	L355R	1.000
19:11454566:A:G	L355P	1.000
19:11454566:A:T	L355Q	1.000
19:11454596:A:G	L345P	1.000
19:11454605:A:T	I342N	1.000
19:11454608:G:T	A341D	1.000
19:11454609:C:G	A341P	1.000
19:11454617:G:T	A338E	1.000
19:11454618:C:G	A338P	1.000
19:11454634:C:A	M332I	1.000
19:11454634:C:G	M332I	1.000
19:11454634:C:T	M332I	1.000
19:11454635:A:C	M332R	1.000
19:11454635:A:G	M332T	1.000
19:11454635:A:T	M332K	1.000
19:11454641:A:T	V330E	1.000
19:11454642:C:T	V330M	1.000
19:11454643:G:C	F329L	1.000
19:11454643:G:T	F329L	1.000
19:11454644:A:C	F329C	1.000
19:11454644:A:G	F329S	1.000

dbSNP variants (sampled 300 via entrez): RS1000091095 (19:11452297 A>C), RS1000426319 (19:11475920 A>G), RS1000439053 (19:11463744 G>A), RS1000549220 (19:11465200 CCACA>C,CCA), RS1000583738 (19:11469454 A>T), RS1000789928 (19:11462456 G>C), RS1000862865 (19:11478810 G>A,T), RS1001000781 (19:11473262 G>A,C), RS1001054492 (19:11473514 C>G), RS1001132968 (19:11454062 T>C), RS1001143224 (19:11479101 A>C), RS1001185574 (19:11470611 G>A), RS1001251695 (19:11453782 GC>G,GCC,GCCCC), RS1001261197 (19:11475613 T>C), RS1001281506 (19:11476522 C>G,T)

Disease associations

OMIM: gene MIM:603458 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST003563_11	Presence of antiphospholipid antibodies	3.000000e-06
GCST003563_12	Presence of antiphospholipid antibodies	4.000000e-06
GCST003563_6	Presence of antiphospholipid antibodies	5.000000e-08
GCST006258_40	Diastolic blood pressure	4.000000e-08
GCST006259_23	Systolic blood pressure	7.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0006336	diastolic blood pressure
EFO:0006335	systolic blood pressure

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4105924 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 97,707 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL50	QUERCETIN	3	74,559
CHEMBL6246	ELLAGIC ACID	2	23,148

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

6 potent at pChembl≥5 of 6 total, top 6 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.70	IC50	200	nM	EPICATECHIN GALLATE
6.70	IC50	200	nM	CHEMBL4088244
6.22	IC50	600	nM	ELLAGIC ACID
6.00	IC50	1000	nM	MYRICETIN
5.92	IC50	1200	nM	RHAMNETIN
5.75	IC50	1800	nM	QUERCETIN

PubChem BioAssay actives

6 with measured affinity, of 6 total; 6 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
[(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate	1450465: Inhibition of ELAV3 (unknown origin)-artificial ARE complex formation after 30 mins in the presence of biotin-labeled RNA probe by chemiluminescence nucleic acid detection method	ic50	0.2000	uM
[(2R,3R)-5-hydroxy-7-methoxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate	1450465: Inhibition of ELAV3 (unknown origin)-artificial ARE complex formation after 30 mins in the presence of biotin-labeled RNA probe by chemiluminescence nucleic acid detection method	ic50	0.2000	uM
6,7,13,14-tetrahydroxy-2,9-dioxatetracyclo[6.6.2.04,16.011,15]hexadeca-1(15),4,6,8(16),11,13-hexaene-3,10-dione	1450465: Inhibition of ELAV3 (unknown origin)-artificial ARE complex formation after 30 mins in the presence of biotin-labeled RNA probe by chemiluminescence nucleic acid detection method	ic50	0.6000	uM
3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one	1450465: Inhibition of ELAV3 (unknown origin)-artificial ARE complex formation after 30 mins in the presence of biotin-labeled RNA probe by chemiluminescence nucleic acid detection method	ic50	1.0000	uM
2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-methoxychromen-4-one	1450465: Inhibition of ELAV3 (unknown origin)-artificial ARE complex formation after 30 mins in the presence of biotin-labeled RNA probe by chemiluminescence nucleic acid detection method	ic50	1.2000	uM
Quercetin	1450465: Inhibition of ELAV3 (unknown origin)-artificial ARE complex formation after 30 mins in the presence of biotin-labeled RNA probe by chemiluminescence nucleic acid detection method	ic50	1.8000	uM

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, increases methylation	8
entinostat	affects cotreatment, increases expression	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	2
Benzo(a)pyrene	affects methylation, decreases methylation, increases expression	2
methylmercuric chloride	increases expression	1
O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	affects expression, affects response to substance	1
ascorbate-2-phosphate	decreases expression, affects binding, affects cotreatment	1
trichostatin A	increases expression	1
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid	affects cotreatment, decreases expression	1
CGP 52608	increases reaction, affects binding	1
Chir 99021	affects binding, affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	increases expression	1
XAV939	affects cotreatment, decreases expression, affects binding	1
LDN 193189	affects cotreatment, increases expression	1
3-(4-pyridyl)-1H-indole	affects cotreatment, decreases expression	1
Decitabine	increases expression	1
Acetaminophen	decreases expression	1
Antimycin A	decreases expression	1
Arsenic	affects methylation	1
Ascorbic Acid	affects binding, affects cotreatment, decreases expression	1
Diethylhexyl Phthalate	decreases expression	1
Hydrocortisone	affects cotreatment, decreases expression	1
Rotenone	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Triclosan	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4018387	Binding	Inhibition of ELAV3 (unknown origin)-artificial ARE complex formation after 30 mins in the presence of biotin-labeled RNA probe by chemiluminescence nucleic acid detection method	Compounds Interfering with Embryonic Lethal Abnormal Vision (ELAV) Protein-RNA Complexes: An Avenue for Discovering New Drugs. — J Med Chem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1SA	Abcam U-87MG ELAVL3 KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.